Correlation between gene expresson of aryl hydrocarbon receptor (AhR), hydrocarbon receptor nuclear translocator (Arnt), cytochromes P4501A1 (CYP1A1) and 1B1 (CYP1B1), and inducibility of CYP1A1 and CYP1B1 in human lymphocytes

Toxicological Sciences

Volumn 71, Issue 1, 2003, Pages 20-26

  Lin, Pinpin ^a   Hu, Suh Woan ^a   Chang, Tzu Hua ^a  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Aryl hydrocarbon receptor; Cytochrome P4501A1; Cytochrome P4501B1; Hydrocarbon receptor nuclear translocator

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; BENZ[A]ANTHRACENE; CARRIER PROTEIN; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; ARNT PROTEIN, HUMAN; BENZ[A]ANTHRACENE DERIVATIVE; CYTOCHROME P 450 CYP1B1; CYTOCHROME P-450 CYP1B1; DNA BINDING PROTEIN; HYPOXIA INDUCIBLE FACTOR 1BETA; MESSENGER RNA; TRANSCRIPTION FACTOR; UNSPECIFIC MONOOXYGENASE;

ADULT; CIGARETTE SMOKING; CONTROLLED STUDY; DATA ANALYSIS; ENZYME INDUCTION; FEMALE; GENDER; GENE EXPRESSION; HUMAN; HUMAN CELL; INCUBATION TIME; LYMPHOCYTE; LYMPHOCYTE CULTURE; MALE; NORMAL HUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; STATISTICAL ANALYSIS; ARTICLE; BIOSYNTHESIS; CELL CULTURE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC VARIABILITY; GENETICS; METABOLISM;

EUKARYOTA;

ADULT; ARYL HYDROCARBON HYDROXYLASES; ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR; BENZ(A)ANTHRACENES; CELLS, CULTURED; CYTOCHROME P-450 CYP1A1; DNA-BINDING PROTEINS; ENZYME INDUCTION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LYMPHOCYTES; MALE; RECEPTORS, ARYL HYDROCARBON; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTORS; VARIATION (GENETICS);

EID: 0037672902     PISSN: 10966080     EISSN: None     Source Type: Journal    
DOI: 10.1093/toxsci/71.1.20     Document Type: Review

References (29)

1. Boffetta, P., Jourenkova, N., and Gustavsson, P. (1997). Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons. Cancer Causes Control 8, 444-472.
2. Chang, K. W., Lee, H., Wang, H. J., Chen, S. Y., and Lin, P. (1999). Differential response to benzo[a]pyrene in human lung adenocarcinoma cell lines: The absence of aryl hydrocarbon receptor activation. Life Sci. 65, 1339-1349.
3. Engeland, A. (1996). Trends in the incidence of smoking-associated cancers in Norway, 1954-93. Int. J. Cancer 68, 39-46.
4. Hayashi, S., Watanabe, J., Nakachi, K., Eguchi, H., Gotoh, O., and Kawajiri, K. (1994). Interindividual difference in expression of human Ah receptor and related P450 genes. Carcinogenesis 15, 801-806.
5. Hecht, S. S. (1999). Tobacco smoke carcinogens and lung cancer. J. Natl. Cancer Inst. 91, 1194-1210.
6. Hirvonen, A., Husgafvel-Pursiainen, K., Karjalainen, A., Anttila, S., and Vainio, H. (1992). Point-mutational MspI and Ile-Val polymorphisms closely linked in the CYP1A1 gene: Lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol. Biomarkers Prev. 1, 485-489.
7. Jacquet, M., Lambert, V., Todaro, A., and Kremers, P. (1997). Mitogen-activated lymphocytes: A good model for characterising lung CYP1A1 inducibility. Eur. J. Epidemiol. 13, 177-183.
8. Kellermann, G., Shaw, C. R., and Luyten-Kellerman, M. (1973). Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. N. Engl. J. Med. 289, 934-937.
9. Kiyohara, C., and Hirohata, T. (1997). Environmental factors and aryl hydrocarbon hydroxylase activity (CYP1A1 phenotype) in human lymphocytes. J. Epidemiol. 7, 244-250.
10. Kiyohara, C., Hirohata, T., and Inutsuka, S. (1996). The relationship between aryl hydrocarbon hydroxylase and polymorphisms of the CYP1A1 gene. Jpn. J. Cancer Res. 87, 18-24.
11. Kiyohara, C., Nakanishi, Y., Inutsuka, S., Takayama, K., Hara, N., Motohiro, A., Tanaka, K., Kono, S., and Hirohata, T. (1998). The relationship between CYP1A1 aryl hydrocarbon hydroxylase activity and lung cancer in a Japanese population. Pharmacogenetics 8, 315-323.
12. Mollerup, S., Ryberg, D., Hewer, A., Phillips, D. H., and Haugen, A. (1999). Sex differences in lung CYP1A1 expression and DNA adduct levels among lung cancer patients. Cancer Res. 59, 3317-3320.
13. Nebert, D. W. (1989). The Ah locus: Genetic differences in toxicity, cancer, mutation, and birth defects. Crit. Rev. Toxicol. 20, 153-174.
14. Nebert, D. W. (1991). Role of genetics and drug metabolism in human cancer risk. Mutat Res 247, 267-281.
15. Perera, F. P. (1996). Molecular epidemiology: Insights into cancer susceptibility, risk assessment, and prevention. J. Natl. Cancer Inst. 88, 496-509.
16. Prasad, R., Prasad, N., Harrell, J. E., Thornby, J., Liem, J. H., Hudgins, P. T., and Tsuang, J. (1979). Aryl hydrocarbon hydroxylase inducibility and lymphoblast formation in lung cancer patients. Int J Cancer 23, 316-320.
17. Prescott, E., Osler, M., Hein, H. O., Borch-Johnsen, K., Lange, P., Schnohr, P., and Vestbo, J. (1998). Gender and smoking-related risk of lung cancer. The Copenhagen Center for Prospective Population Studies. Epidemiology 9, 79-83.
18. Shehin, S. E., Stephenson, R. O., and Greenlee, W. F. (2000). Transcriptional regulation of the human CYP1B1 gene: Evidence for involvement of an aryl hydrocarbon receptor response element in constitutive expression. J. Biol. Chem. 275, 6770-6776.
19. Shimada, T., Hayes, C. L., Yamazaki, H., Amin, S., Hecht, S. S., Guengerich, F. P., and Sutter, T. R. (1996). Activation of chemically diverse procarcinogens by human cytochrome P450 1B1. Cancer Res. 56, 2979-2984.
20. Shimada, T., Yun, C. H., Yamazaki, H., Gautier, J. C., Beaune, P. H., and Guengerich, F. P. (1992). Characterization of human lung microsomal cytochrome P-450 1A1 and its role in the oxidation of chemical carcinogens. Mol. Pharmacol. 41, 856-864.
21. Shimizu, Y., Nakatsuru, Y., Ichinose, M., Takahashi, Y., Kume, H., Mimura, J., Fujii-Kuriyama, Y., and Ishikawa, T. (2000). Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor. Proc. Natl. Acad. Sci. USA 97, 779-782.
22. Smart, J., and Daly, A. K. (2000). Variation in induced CYP1A1 levels: Relationship to CYP1A1, Ah receptor, and GSTM1 polymorphisms. Pharmacogenetics 10, 11-24.
23. Spencer, D. L., Masten, S. A., Lanier, K. M., Yang, X., Grassman, J. A., Miller, C. R., Sutter, T. R., Lucier, G. W., and Walker, N. J. (1999). Quantitative analysis of constitutive and 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced cytochrome P450 1B1 expression in human lymphocytes. Cancer Epidemiol. Biomarkers Prev. 8, 139-146.
24. Stucker, I., Jacquet, M., de Waziers, I., Cenee, S., Beaune, P., Kremers, P., and Hemon, D. (2000). Relation between inducibility of CYP1A1, GSTM1 and lung cancer in a French population. Pharmacogenetics 10, 617-627.
25. Tefre, T., Ryberg, D., Haugen, A., Nebert, D. W., Skaug, V., Brogger, A., and Borresen, A. L. (1991). Human CYP1A1 (cytochrome P(1)450) gene: Lack of association between the Msp-I restriction fragment-length polymorphism and incidence of lung cancer in a Norwegian population. Pharmacogenetics 1, 20-25.
26. Ward, E., Paigen, B., Steenland, K., Vincent, R., Minowada, J., Gurtoo, H. L., Sartori, P., and Havens, M. B. (1978). Aryl hydrocarbon hydroxylase in persons with lung or laryngeal cancer. Int. J. Cancer 22, 384-389.
27. Whitlock, J. P., Jr. (1999). Induction of cytochrome P4501A1. Annu. Rev. Pharmacol. Toxicol. 39, 103-125.
28. Xu, X., Kelsey, K. T., Wiencke, J. K., Wain, J. C., and Christiani, D. C. (1996). Cytochrome P450 CYP1A1 MspI polymorphism and lung cancer susceptibility. Cancer Epidemiol. Biomarkers Prev. 5, 687-692.
29. Zang, E. A., and Wynder, E. L. (1996). Differences in lung cancer risk between men and women: Examination of the evidence. J. Natl. Cancer Inst. 88, 183-192.